Atlas Trials

A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

Clinical trial NCT02713256 · COMPLETED

Trial details

NCT number
NCT02713256
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Graves' Disease
Start date
2016-04-19
Primary completion
2017-04-24
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.